ArticleInternational journal of molecular sciences2023
Fatty Liver Index (FLI) Identifies Not Only Individuals with Liver Steatosis but Also at High Cardiometabolic Risk.
Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Plasma metabolic signatures of healthy dietary patterns and risk of metabolic dysfunction-associated steatotic liver disease and cirrhosis.Hepatology international · 2026Article
- [Metabolic Dysfunction-Associated Steatotic Liver Disease and its association with prediabetes in adolescents with obesity].Revista medica del Instituto Mexicano del Seguro Social · 2026Article
- Association between hypertension and fatty liver index in patients undergoing coronary computed tomography angiography: a cross-sectional study.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Fatty liver index in early pregnancy predicts the risk of gestational diabetes mellitus.Frontiers in endocrinology · 2026Article
- Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J-mono post hoc analysis.Diabetes, obesity & metabolism · 2026Article
- Assessment of Hepatic Safety of Ulipristal Acetate in Korean Women with Uterine Fibroids: A Real-World Study Using Biochemical Markers.Journal of clinical medicine · 2025Article
- Nonlinear relationship between body fat percentage and NAFLD mediated by METS-IR: threshold effects and subgroup differences.Scientific reports · 2025Article
- The association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and hepatic steatosis and liver fibrosis among US adults based on NHANES.Scientific reports · 2025Article
- Association between surrogate indices of fatty liver and the risk of colorectal cancer: a cross-sectional United States study.Translational cancer research · 2025Article
- Exploring BMI's mediating influence on cardiovascular risk correlations with the triglyceride-glucose index: using NHANES and CHARLS cohorts.Frontiers in cardiovascular medicine · 2025Article
- Screening for the Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Among Patients With Prediabetes and Type 2 Diabetes: A Comparison of Three Screening Systems.International journal of endocrinology · 2025Article
- Association of life's essential 8 with all-cause and cause-specific mortality in metabolic dysfunction-associated steatotic liver disease.Scientific reports · 2024Article
- Correlation of serum cotinine with fatty liver index in adults: data from the NHANES March 2017 and 2018.BMC gastroenterology · 2024Article
- Article
- A Systematic Review of Metabolic Syndrome: Key Correlated Pathologies and Non-Invasive Diagnostic Approaches.Journal of clinical medicine · 2024Review
- Association between composite dietary antioxidant index and fatty liver index among US adults.Frontiers in nutrition · 2024Article
- Unveiling the Hepatic Harbinger: Assessing the Fatty Liver Index as a Predictor of Metabolic Syndrome in Female Healthcare Workers.Indian journal of occupational and environmental medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
A fatty liver index (FLI) greater than sixty (FLI ≥ 60) is an established score for metabolic dysfunction-associated steatotic liver disease (MASLD), which carries a high risk for diabetes and cardiovascular disease, while a FLI ≤ 20 rules out the presence of steatosis. Thus, we investigated whether FLI was associated with cardiometabolic risk factors, i.e., visceral (VAT), subcutaneous (SC), epicardial (EPI), extrapericardial (PERI), and total cardiac (CARD-AT) adipose tissue, hepatic fat ((by magnetic resonance imaging, MRI, and spectroscopy, MRS), and insulin resistance (IR, HOMA-IR and OGIS-index), and components of metabolic syndrome. All individuals with FLI ≥ 60 had MASLD, while none with FLI ≤ 20 had steatosis (by MRS). Subjects with FLI ≥ 60 had a higher BMI and visceral and cardiac fat (VAT > 1.7 kg, CARD-AT > 0.2 kg). FLI was positively associated with increased cardiac and visceral fat and components of metabolic syndrome. FLI, VAT, and CARD-AT were all associated with IR, increased blood pressure, cholesterol, and reduced HDL. For FLI ≥ 60, the cut-off values for fat depots and laboratory measures were estimated. In conclusion, FLI ≥ 60 identified not only subjects with steatosis but also those with IR, abdominal and cardiac fat accumulation, increased blood pressure, and hyperlipidemia, i.e., those at higher risk of cardiometabolic diseases. Targeted reduction of FLI components would help reduce cardiometabolic risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.